Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05309460 · ClinicalTrials.gov registry record · Phase 4

Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial

A Phase 4 study of Hypertension in Pregnancy and Postpartum Preeclampsia, sponsored by Nebraska Methodist Health System.

Recruiting
Registry status
Phase 4
Development phase
600
Enrollment target
1
Study location

NCT05309460: Recruiting Phase 4 study of Hypertension in Pregnancy and Postpartum Preeclampsia, sponsored by Nebraska Methodist Health System.

NCT05309460 is a Phase 4 study of Hypertension in Pregnancy and Postpartum Preeclampsia that is actively recruiting participants, run by Nebraska Methodist Health System. The registered enrollment target is 600 participants, above the 402-participant average among 13 other Hypertension in Pregnancy trials with a reported enrollment target (49% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05309460, a Phase 4 study of Hypertension in Pregnancy and Postpartum Preeclampsia, is actively recruiting participants, sponsored by Nebraska Methodist Health System.

RECRUITING
Registry status
Phase 4
Development phase
600 participants
Enrollment target
1
Study location

Study Summary

Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.

Primary Outcome

Patients will be monitored following delivery for readmission to the hospital. To improve patient capture, all patients will be called at 6 months to identify complications or if hospital admission occured in the 6 months following delivery

Interventions

  • DRUG Labetalol Oral Tablet
  • DRUG NIFEdipine ER

Study Locations (1)

Nebraska

  • Nebraska Methodist Women's Hospital - Omaha

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2022-06-20
Est. Completion 2024-12-01
Phase Phase 4
Nebraska Methodist Health System

5 total trials

What NCT05309460 shows while recruiting

NCT05309460 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 402-participant average among 13 other Hypertension in Pregnancy trials with a reported enrollment target (49% higher).

The record links to 2 conditions, with Hypertension in Pregnancy appearing as the primary indexed condition, and to 2 interventions - of which Labetalol Oral Tablet is the first listed.

NCT05309460 reports a single indexed study location in Nebraska.

Frequently Asked Questions

What is clinical trial NCT05309460 about?

NCT05309460 is a clinical study titled "Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial". Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.

What is the current status of trial NCT05309460?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 2022-06-20. Estimated completion is 2024-12-01.

What conditions does trial NCT05309460 study?

This clinical trial studies the following conditions: Hypertension in Pregnancy, Postpartum Preeclampsia.

What interventions are being tested in trial NCT05309460?

The interventions under investigation include: Labetalol Oral Tablet (DRUG), NIFEdipine ER (DRUG).

Who is sponsoring clinical trial NCT05309460?

This trial is sponsored by Nebraska Methodist Health System, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05309460 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension in Pregnancy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05309460's enrollment target sits among peer trials

600 4th of 13 higher than 10 of 13 other Hypertension in Pregnancy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension in Pregnancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05309460, the US trial registry maintained by the National Library of Medicine. NCT05309460 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.